Real-world evidence supports clinical effectiveness of neffy®/EURneffy® in U.S. patients experiencing anaphylaxis

8 September 2025 - ALK today shares real-world evidence evaluating the clinical performance of neffy^®/EURneffy^® (nasal adrenaline spray) in patients experiencing allergic reactions during oral food challenge and allergen immunotherapy. These findings represent the first analysis of treatment outcomes with neffy^®/EURneffy^® 2 mg during routine clinical practice, and have been accepted as a correspondence in the Annals of Allergy, Asthma and Immunology, the official journal of the American College of Allergy, Asthma and Immunology. This study was conducted in the United States (U.S.) using the product known as neffy^®. EURneffy^® is the brand name approved in UK.

Nearly 90% (89.2%) of 545 patients experiencing allergic reactions during oral food challenge and allergen immunotherapy were successfully treated with a single dose of neffy^®/EURneffy^® by a healthcare professional.¹ Meta-analyses report a similar proportion of patients, 88.9%, being successfully treated with a single dose of adrenaline intramuscular injection or auto-injector by a healthcare professional for food-induced anaphylaxis.² The successful real-world use of neffy^®/EURneffy^® by health professionals to treat allergic reactions is very similar to adrenaline injections. Only 59 patients (10.8%) required a second dose of adrenaline, which is within the range of second doses required following food-induced anaphylaxis (11.1%).^1,2

“I was interested to see the results of this first report of real-world treatment outcomes relating to EURneffy^® during anaphylaxis. In over 500 patients in the U.S., the findings that about 9 in 10 were successfully treated with a single dose of neffy^®/EURneffy^®, and 1 in 10 required a second dose, are essentially identical to the historic response rates seen with adrenaline injection,” said Prof George Du Toit, Professor of Paediatric Allergy at the Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London. “I believe these real-world findings support the clinical interchangeability of EURneffy^® and adrenaline injection, complementing the studies provided for regulatory approval that demonstrated EURneffy^® achieved comparable blood levels and pharmacodynamic responses to traditional approved adrenaline auto-injectors.”

EURneffy^® is a ready to use, needle-free nasal adrenaline spray approved for use by the Medicines and Healthcare Products Regulatory Agency (MHRA) for timely emergency anaphylaxis treatment in adults and children (≥30 kg) in the UK in July 2025.³ EURneffy^® offers a useful,⁴ convenient and simple to use⁵ alternative for people with life-threatening allergies.